-
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
12 Nov 2024 21:45 GMT
… Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. SOURCE: Cyclacel Pharmaceuticals, Inc.
CYCLACEL PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS … ,167
)
(6,700
)
Income tax benefit
210
668
Net loss
(1 …
-
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q2 2024 Earnings Call Transcript
15 Aug 2024 13:28 GMT
… from an unselected population.
Clinical benefit was observed in heavily pre … weeks. In addition, clinical benefit was reported in two patients … day. Goodbye.
Follow Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) Follow Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC …
-
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
14 Aug 2024 20:05 GMT
… Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. SOURCE: Cyclacel Pharmaceuticals, Inc.
CYCLACEL PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS … ,669
)
(6,034
)
Income tax benefit
412
586
Net loss
(3 …
-
Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
03 Jun 2024 12:00 GMT
… 1 population at ASCO. Clinical benefit was observed in heavily pretreated … .1 criteria. In addition, clinical benefit was reported in two patients … or otherwise. Contacts © Copyright 2024 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The …
-
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q1 2024 Earnings Call Transcript
15 May 2024 12:17 GMT
… , and recently testicular who benefited from fadraciclib monotherapy. These … all of whom experienced clinical benefit after Fadra monotherapy. These … A Session Follow Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) Follow Cyclacel Pharmaceuticals Inc. (NASDAQ …
-
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
14 May 2024 20:05 GMT
… trademarks of Cyclacel Pharmaceuticals, Inc. SOURCE: Cyclacel Pharmaceuticals, Inc.
CYCLACEL PHARMACEUTICALS, INC …
(7,124
)
Income tax benefit
1,354
1 …
835,946
CYCLACEL PHARMACEUTICALS, INC.
CONSOLIDATED BALANCE SHEET
(In …
-
Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript
20 Mar 2024 00:04 GMT
… and welcome to the Cyclacel Pharmaceuticals Fourth Quarter and Full … and pancreatic who have benefited from fadraciclib monotherapy. These … patients who experienced clinical benefit with fadra, we … SMARCA mutated cancers may benefit from treatment of plogo …
-
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
19 Mar 2024 20:05 GMT
… , hepatobiliary, lung, and pancreatic, who benefitted from fadraciclib monotherapy. In addition … Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. SOURCE: Cyclacel Pharmaceuticals, Inc.
CYCLACEL PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS …
-
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
18 Dec 2023 14:00 GMT
… patients who experienced clinical benefit with fadra, we found … laboratories are completed. About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a … ® are trademarks of Cyclacel Pharmaceuticals, Inc. SOURCE: Cyclacel Pharmaceuticals, Inc. _______________ 1 …
-
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q3 2023 Earnings Call Transcript
14 Nov 2023 16:10 GMT
… , and welcome to the Cyclacel Pharmaceuticals Third Quarter 2023 Results Conference … the tumor subsets that will benefit the most from this approach … ;A Session Follow Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) Follow Cyclacel Pharmaceuticals Inc. (NASDAQ: …
About
© 1995-2025